688382.SHG InventisBio Co. Ltd. A

Healthcare Biotechnology Shanghai Stock Exchange
13.85 CNY
Close of Nov 4, 2026
11.88 34.60
Market cap
CNY 8.03B
P/E
-
P/B
5.28x
ROE
-19.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 688382.SHG undervalued?

Graham number

The Graham number of InventisBio Co. Ltd. A cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

InventisBio Co. Ltd. A fundamental analysis

No fundamental analysis for InventisBio Co. Ltd. A yet.

InventisBio Co. Ltd. A stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About InventisBio Co. Ltd. A

InventisBio Co., Limited, a clinical stage biotech company, focuses on areas of oncology, autoimmune diseases, and metabolic disorders to address unmet medical needs in China. Its product pipeline for the oncology therapeutic area include Befoternitib (BPI-D0316), which is in Phase III clinical trial for the non-small cell lung cancer (NSCLS) indications; Garsorasib (D-1553), which is in phase II and III clinical trials to treat NSCLS and colorectal cancer; Taragarestrant (D…

Full company profile